Yazarlar : Arai K, Orsoni A, Mallat Z, Tedgui A, Witztum JL, Bruckert E, Tselepis AD, Chapman MJ, Tsimikas S.

Yayın : J Lipid Res.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22628616

Konu : Aferez

Literatür İçeriği :  

Abstract

We measured oxidized phospholipids (OxPL), lipoprotein (a) [Lp(a)] and lipoprotein-associated phospholipase A2 (Lp-PLA2) pre- and post-apheresisin 18 patients with familial hypercholesterolemia (FH) and Low (~10mg/dL; range 10-11 mg/dL), Intermediate (~50mg/dL; range 30-61 mg/dL) or High (>100mg/dL; range 78-128 mg/dL) Lp(a) levels. Using enzymatic and immunoassays, the content of OxPL and Lp-PLA2 mass and activity were quantitated in lipoprotein density fractions plated in microtiter wells, as well as directly on apoB-100, Lp(a) and apoA-I immunocaptured within each fraction (i.e. OxPL/apoB and Lp-PLA2/apoB). In whole fractions, OxPL were primarily detected in the Lp(a)-containing fractions, while Lp-PLA2 in the small-dense LDL and light Lp(a) range. In lipoprotein capture assays, OxPL/apoB and OxPL/apo(a) increased proportionally with increasing Lp(a) levels. Lp-PLA2/apoB and Lp-PLA2/apoA-I levels were highest in the Low Lp(a) group, but decreased proportionally with increasing Lp(a) levels. Lp-PLA2/apo(a) was lowest in patients with Low Lp(a) levels and increased proportionally with increasing Lp(a) levels. Apheresis significantly reduced levels of OxPL and Lp-PLA2 on apoB and Lp(a) (50-75%), particularly in patients with Intermediate and High Lp(a) levels. In contrast, apheresisincreased Lp-PLA2 specific activity (activity/mass ratio) in buoyant LDL fractions. The impact of apheresis on Lp(a), OxPL and Lp-PLA2 provides insights into its therapeutic benefits beyond lowering apoB-containing lipoproteins.

Literatür Arşivi